Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

被引:16
|
作者
Hillengass, Jens [1 ]
Zechmann, Christian M. [2 ]
Nadler, Andreas [1 ]
Hose, Dirk
Cremer, Friedrich W. [3 ]
Jauch, Anna [3 ]
Heiss, Christiane [4 ,5 ]
Benner, Axel [4 ]
Ho, Anthony D. [1 ]
Bartram, Claus R.
Kauczor, Hans-Ulrich [2 ]
Delorme, Stefan [2 ]
Goldschmidt, Hartmut [1 ,5 ]
Moehler, Thomas M. [1 ]
机构
[1] Univ Heidelberg, Dept Hematol Oncol & Rheumatol, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Dept Radiol, D-6900 Heidelberg, Germany
[3] Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany
[4] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Sect Multiple Myeloma, Heidelberg, Germany
关键词
multiple myeloma; monoclonal gammopathy of undetermined significance; dynamic contrast-enhanced magnetic resonance imaging; cytogenetics; in situ fluorescence hybridization;
D O I
10.1002/ijc.23455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n = 31) and untreated multiple myeloma (MM) (n = 87) patients. The adverse cytogenetic abnormalities gain of 1q21, deletion 17p13 and deletion 13q14 significantly correlated with at least one DCE-MRI finding (aberrant "focal" microcirculation pattern, increase in median microcirculation parameter Amplitude A or exchange rate constant kep). We conclude that gain of 1q21, deletion 13q14 and deletion 17p13 trigger the angiogenic cascade in MM. Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2871 / 2875
页数:5
相关论文
共 50 条
  • [41] Poor prognosis associated with gain of chromosome 1Q21 in multiple myeloma may be overcome by treatment with a bortezomib combination
    Sagaster, V.
    Odelga, V.
    Kaufmann, H.
    Ackermann, J.
    Galhuber, M.
    Zojer, N.
    Ludwig, H.
    Wieser, R.
    Zielinski, C.
    Drach, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 149
  • [42] Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
    Pan, Darren
    Kaufman, Jonathan L.
    Htut, Myo
    Agrawal, Manish
    Mazumder, Amitabha
    Cornell, Robert F.
    Zonder, Jeffrey A.
    Fay, Joseph W.
    Modiano, Manuel R.
    Moshier, Erin L.
    Rush, Selena A.
    Tunquist, Brian J.
    Chari, Ajai
    CANCER MEDICINE, 2022, 11 (02): : 358 - 370
  • [43] The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides
    Xu, Jiadai
    Xu, Tianhong
    Yang, Yang
    Wang, Wenjing
    Li, Jing
    Ren, Yuhong
    Gu, Shiyang
    Chen, Chen
    Wei, Zheng
    Zhuang, Jingli
    Wang, Zhimei
    Ji, Lili
    Cheng, Luya
    Wang, Weiguang
    Cheng, Zhixiang
    Ke, Yang
    Yuan, Ling
    Liu, Peng
    LEUKEMIA & LYMPHOMA, 2020, 61 (10) : 2351 - 2364
  • [44] Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains
    Chang, Hong
    Trieu, Young
    Qi, Xiaoying
    Jiang, Nan N.
    Xu, Wei
    Reece, Donna
    LEUKEMIA RESEARCH, 2011, 35 (01) : 95 - 98
  • [45] Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
    Burroughs Garcia, Jessica
    Eufemiese, Rosa Alba
    Storti, Paola
    Sammarelli, Gabriella
    Craviotto, Luisa
    Todaro, Giannalisa
    Toscani, Denise
    Marchica, Valentina
    Giuliani, Nicola
    CELLS, 2021, 10 (06)
  • [46] Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
    Slomp, Anne
    Moesbergen, Laura M.
    Gong, Jia-nan
    Cuenca, Marta
    von dem Borne, Peter A.
    Sonneveld, Pieter
    Huang, David C. S.
    Minnema, Monique C.
    Peperzak, Victor
    BLOOD ADVANCES, 2019, 3 (24) : 4202 - 4214
  • [47] Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients
    Lim, Kenneth J. C.
    Wellard, Cameron
    Moore, Elizabeth
    Ninkovic, Slavisa
    Chng, Wee Joo
    Spencer, Andrew
    Mollee, Peter
    Hocking, Jay
    Ho, Phoebe Joy
    Janowski, Wojt
    Kim, Kihyun
    Mccaughan, Georgia
    Dun, Karen
    Mcquilten, Zoe K.
    Chen, Fiona
    Quach, Hang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04): : 243 - 248
  • [48] Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
    Nemec, Pavel
    Zemanova, Zuzana
    Greslikova, Henrieta
    Michalova, Kyra
    Filkova, Hana
    Tajtlova, Jana
    Kralova, Dana
    Kupska, Renata
    Smetana, Jan
    Krejci, Marta
    Pour, Ludek
    Zahradova, Lenka
    Sandecka, Viera
    Adam, Zdenek
    Buchler, Tomas
    Spicka, Ivan
    Gregora, Evzen
    Kuglik, Petr
    Hajek, Roman
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (04) : 548 - 554
  • [49] Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
    Nahi, Hareth
    Vatsveen, Thea Kristin
    Lund, Johan
    Heeg, Bart M. S.
    Preiss, Birgitte
    Alici, Evren
    Moller, Michael Boe
    Wader, Karin Fahl
    Moller, Hanne E. H.
    Groseth, Lill Anny
    Ostergaard, Brian
    Dai, Hong Yan
    Holmberg, Erik
    Gahrton, Gosta
    Waage, Anders
    Abildgaard, Niels
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (01) : 46 - 54
  • [50] The frequency and clinico-hematological characteristics of gain(1q21) positive myeloma in an Indian cohort
    Panakkal, Vandana
    Sreedharanunni, Sreejesh
    Rana, Sonia
    Rathore, Shailja
    Chanalia, Aman
    Lad, Deepesh
    Sachdeva, Man Updesh Singh
    Varma, Neelam
    Malhotra, Pankaj
    LEUKEMIA RESEARCH, 2021, 105